Skip to main content

Table 3 Risk factors affecting nab-paclitaxel monotherapy related adverse events and efficacy outcomes by meta-regression analysis

From: A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

Effect Index Risk Factors Coef. value Std. Err. T value P value 95% Confidence Interval
Incidence of neutropenia
3/4 grade
Her-2 negative −0.136 0.063 −2.14 0.046 −0.268 to −0.003
Incidence of leukopenia
all grades
Treatment line 0.366 0.148 2.48 0.056 −0.014 to 0.746
Incidence of neuropathy
3/4 grade
Nab-paclitaxel dosage 0.201 0.107 1.87 0.078 −0.025 to 0.427
Incidence of fatigue
all grades
Treatment line −0.239 0.100 −2.40 0.032 −0.455 to − 0.024
ORR Treatment line −0.180 0.059 −3.03 0.006 −0.302 to − 0.058
Nab-paclitaxel dosage 0.171 0.081 2.11 0.044 0.005 to 0.338
CBR Treatment line −0.176 0.077 −2.29 0.037 −0.340 to − 0.012
PFS Treatment line 1.398 0.635 2.20 0.045 0.036 to 2.760
Nab-paclitaxel dosage 2.683 1.114 2.41 0.030 0.295 to 5.071
OS Treatment line −18.909 8.210 −2.30 0.040 −36.797 to −1.021